How does rilzabrutinib stop my immune system from destroying my platelets?
Rilzabrutinib blocks a protein called Bruton's tyrosine kinase (BTK) in your B cells and immune cells. This stops your body from making antibodies that attack platelets and prevents your spleen from destroying antibody-coated platelets. In clinical trials, 73% of patients achieved safe platelet counts within 4 weeks [1][2].
Rilzabrutinib is a reversible covalent BTK inhibitor—a small molecule that binds to and temporarily shuts down a key enzyme in B cells and immune cells [2]. In immune thrombocytopenia (ITP), your body mistakenly makes antibodies that coat your platelets, marking them for destruction. Rilzabrutinib blocks two critical steps: it stops B cells from activating and making more antibodies, and it interrupts the signal that tells your spleen to destroy antibody-coated platelets [1].
Inside your body, rilzabrutinib works through the Fcγ receptor (FcγR) pathway—the communication system your spleen uses to recognize and destroy antibody-coated cells [2]. By blocking BTK signaling, the drug reduces autoantibody generation and prevents the spleen's immune cells from engulfing your platelets [1]. Think of it as turning down the volume on the alarm that tells your spleen to attack [3].
In the LUNA3 phase 3 trial, 73% of rilzabrutinib patients reached platelet counts ≥30,000/μL (safe for daily life) compared to only 7% on placebo [1]. Most patients saw improvement within 2–4 weeks, and the response lasted 12+ months with continued daily dosing [3]. Your doctor will check your blood count every 2 weeks at first to confirm the dose is working and safe [2].
Ask your doctor: 'How often will you check my platelet count, and what number means my dose is working?' Most clinicians recheck labs every 2 weeks for the first month, then monthly. Write down your target platelet count (usually ≥30,000/μL) so you can track progress at home [1].